

## Building the Oligonucleotide Safeguard Platform Business(Liid Pharmaceuticals, Inc.)



City	Year of Establishment	Founder
Suita, Osaka	2019	Fumito Wada Mariko Hrada-Shiba

Partner VC	Latest round of Fundraising	Valuation
Greencore Co., Ltd.	Pre-Series A	JPY 1,253million

Contact Information : [info@liidpharma.co.jp](mailto:info@liidpharma.co.jp)

Website : <https://liidpharma.co.jp/top-eng/>

### ○ Business Plan

The objective of this project is the commercialization of the BROTHERS technology platform, which enhances the safety of antisense oligonucleotide (ASO) drugs. This involves establishing the necessary CMC (Chemistry, Manufacturing, and Controls) framework for the PNA strand, which functions as the safeguard, and obtaining the essential data package required for pharmaceutical development support.

### ○ Research Outline

In this R&D project, we will develop "BROTHERS," an enhanced version of conventional antisense oligonucleotides (ASO). We aim to resolve the challenges associated with conventional ASOs by employing a PNA strand that functions as a safeguard. Furthermore, we will establish a drug development support business utilizing this technology by executing the following:

- ① Development of standard manufacturing processes (CMC) for BROTHERS
- ② Development of standard formulations and stability evaluation
- ③ Acquisition of standard pharmacokinetic (PK/PD) profiles

Business Area/Field	Research Period	Research Grant Amount	International collaborative technology demonstration
Healthcare	STS 2025-2026FY	JPY 300 million	-